don't disagree that it's attractive. but you're assuming management can actually deliver. There have been a few failures in the past - i.e. Ultralute that was supposed to be a new product but shelved.
Not saying it isn't attractive, but at close to US$300m market cap off less than $5m of profit even after adding back FDA expenses it's not quite as cheap as it once was - you have to believe in the vision to buy at these prices
Ann: SNMMI Announcement Regarding USFDA Approval of Technegas, page-3
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.010(0.59%) |
Mkt cap ! $187.8M | |||
| Open | High | Low | Value | Volume |
| $1.70 | $1.71 | $1.66 | $122.2K | 72.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 684 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 19414 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CYC (ASX) Chart |